IL324773A - תכשירי רוקחות - Google Patents

תכשירי רוקחות

Info

Publication number
IL324773A
IL324773A IL324773A IL32477325A IL324773A IL 324773 A IL324773 A IL 324773A IL 324773 A IL324773 A IL 324773A IL 32477325 A IL32477325 A IL 32477325A IL 324773 A IL324773 A IL 324773A
Authority
IL
Israel
Prior art keywords
pharmaceutical composition
microcrystalline cellulose
dicalcium phosphate
solid dosage
dosage form
Prior art date
Application number
IL324773A
Other languages
English (en)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of IL324773A publication Critical patent/IL324773A/he

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL324773A 2023-05-26 2024-05-24 תכשירי רוקחות IL324773A (he)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP23175788 2023-05-26
PCT/EP2024/064426 WO2024245953A1 (en) 2023-05-26 2024-05-24 Pharmaceutical compositions

Publications (1)

Publication Number Publication Date
IL324773A true IL324773A (he) 2026-01-01

Family

ID=86605004

Family Applications (1)

Application Number Title Priority Date Filing Date
IL324773A IL324773A (he) 2023-05-26 2024-05-24 תכשירי רוקחות

Country Status (15)

Country Link
EP (1) EP4719359A1 (he)
JP (1) JP2026518000A (he)
KR (1) KR20260016534A (he)
CN (1) CN121175036A (he)
AR (1) AR132774A1 (he)
AU (1) AU2024279893A1 (he)
CL (1) CL2025003668A1 (he)
CO (1) CO2025018521A2 (he)
CR (1) CR20250538A (he)
DO (1) DOP2025000289A (he)
IL (1) IL324773A (he)
MX (1) MX2025014102A (he)
PE (1) PE20260438A1 (he)
TW (1) TW202510865A (he)
WO (1) WO2024245953A1 (he)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0818533B8 (pt) 2007-10-11 2021-05-25 Astrazeneca Ab composto, composição farmacêutica, uso de um composto, e, processo para a preparação de um composto
AU2013204533B2 (en) 2012-04-17 2017-02-02 Astrazeneca Ab Crystalline forms
WO2022147519A1 (en) * 2021-01-04 2022-07-07 Teva Pharmaceuticals International Gmbh Solid state forms of capivasertib and process for preparation thereof
CN119278041A (zh) * 2022-03-31 2025-01-07 阿斯利康(瑞典)有限公司 用于治疗癌症的与akt抑制剂组合的表皮生长因子受体(egfr)酪氨酸激酶抑制剂

Also Published As

Publication number Publication date
MX2025014102A (es) 2026-01-07
CN121175036A (zh) 2025-12-19
TW202510865A (zh) 2025-03-16
CO2025018521A2 (es) 2026-01-13
PE20260438A1 (es) 2026-02-19
WO2024245953A1 (en) 2024-12-05
EP4719359A1 (en) 2026-04-08
AR132774A1 (es) 2025-07-30
DOP2025000289A (es) 2026-01-15
AU2024279893A1 (en) 2026-01-22
CR20250538A (es) 2026-04-21
JP2026518000A (ja) 2026-06-02
KR20260016534A (ko) 2026-02-03
CL2025003668A1 (es) 2026-03-13

Similar Documents

Publication Publication Date Title
CN105025886B (zh) 地拉罗司(deferasirox)的口服制剂
CA3073568A1 (en) High concentration dosage forms of pridopidine
Priyanka et al. A comprehensive review on pharmaceutical mini tablets
EP2538924B1 (en) Solid pharmaceutical formulations of ramipril and amlodipine besylate, and their preparation
US12453729B2 (en) Pharmaceutical formulations
Neeharika et al. Preparation and evaluation of zafirlukast compression coated tablets for chronotherapeutic drug delivery
WO2024245953A1 (en) Pharmaceutical compositions
CN113811294B (zh) 用于治疗或预防高血压和高脂血症的单一剂型药物组合物
BR112020006995A2 (pt) formas de dosagem de dissuasão de abuso de liberação modificada
Patil et al. Chronomodulated press-coated pulsatile therapeutic system for aceclofenac: optimization of factors influencing drug release and lag time
Dembla et al. Formulation development and evaluation of gabapentin controlled release tablets
CN102238944A (zh) 用于制备生物粘附压制基质的方法
Akbar et al. Development and characterization of atorvastatin calcium sustained release tablet using carbomer-974 and hypromellose-15000 cps
Bello Physiochemical and drug release properties of Liquisolid formulations in comparison to their physical mixture counterparts
Kumar et al. Design, formulation and evaluation of sustained release bilayer tablets of ciprofloxacin hydrochloride
Purkar et al. Formulation Development and Evaluation of Quetiapine fumarate Extended-Release tablet by using 2 3 Factorial designs
Singh et al. Colon specific chronotherapeutic drug delivery for nocturnal asthma: effect of Eudragit enteric coating on matrix tablets of salbutamol sulphate
WO2025265110A1 (en) Oral pharmaceutical compositions comprising a naphthyridine compound
EA048243B1 (ru) Фармацевтический состав
Barde et al. Development and In Vitro Evaluation of Extended Release Matrix Tablet of Metoprolol Succinate
TW202224681A (zh) 用於治療或預防高血壓及高膽固醇血症之單一劑型的醫藥組成物
Rameshgiri Development and Evaluation of Controlled Release Matrix Tablets of Diltiazem Hydrochloride Using Natural Polymers
WO2021118403A1 (ru) Система доставки 2-этил-6-метил-3-гидроксипиридина сукцината для перорального применения
Patel Formulation and evaluation of ranolazine sustained release tablets by hot melt coating technique
Sitarambhai Formulation and Evaluation of Sustained Release Levofloxacin Matrix Tablets